Biotech · Public company · Waltham, MA, US

Mustang Bio, Inc.

Ticker MBIO · SEC CIK 0001680048

Track this companyFree. Adds Mustang Bio, Inc. to your Dealase workspace and tells you when its record changes.

Clinical trials52 recruiting or active

Pipeline programs6From trials and the company's site

Disclosed deals0None found yet

Cash runwayNot availableNo recent cash burn filed

Pipeline6

CyclophosphamidePhase 2 · Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)ClinicalTrials.gov · fetched Nov 12, 2026
FludarabinePhase 2 · Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)ClinicalTrials.gov · fetched Nov 12, 2026
MB-102Phase 2 · Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)ClinicalTrials.gov · fetched Nov 12, 2026
MB-106Phase 2 · Follicular B-cell Non-Hodgkin's LymphomaClinicalTrials.gov · fetched Nov 12, 2026
Prior MB-102 CAR-T cell investigational product.Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)ClinicalTrials.gov · fetched Nov 12, 2026
Prior MB-106 CAR-T cell investigational product.Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)ClinicalTrials.gov · fetched Nov 12, 2026

Study to Assess Safety, Tolerability and Efficacy of MB-106 in Patients With Relapsed or Refractory B-Cell NHL or CLLPHASE1_PHASE2 · TERMINATED · started May 24, 2022ClinicalTrials.gov NCT05360238 · fetched Nov 12, 2026
Long-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR-T Cell Investigational Product.TERMINATED · started Sep 29, 2021ClinicalTrials.gov NCT05645744 · fetched Nov 12, 2026
Trial to Evaluate the Safety and Efficacy of MB-102 in Patients With BPDCN.PHASE1_PHASE2 · TERMINATED · started Feb 17, 2020ClinicalTrials.gov NCT04109482 · fetched Nov 12, 2026
A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin LymphomasPHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started Dec 5, 2017ClinicalTrials.gov NCT03277729 · fetched Nov 12, 2026
Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell NeoplasmPHASE1 · ACTIVE_NOT_RECRUITING · started Dec 15, 2015ClinicalTrials.gov NCT02159495 · fetched Nov 12, 2026